The BSRBR Rheumatoid Arthritis Register



The BSRBR-RA is run by the Arthritis Research UK Epidemiology Unit at the University of Manchester. It tracks the progress of patients with severe rheumatoid arthritis (RA), who are receiving biologic agents (adalimumab, anakinra, benepali, certolizumab pegol, etanercept, infliximab, rituximab and tocilizumab currently), monitoring the safety and effectiveness of these treatments over the long term.

Patients are registered and followed up to assess their response to treatment and to capture detailed information about serious adverse events. Patients are flagged with the NHS Information Centre, which notifies BSRBR-RA of any cases of cancer and any deaths and their causes. Data is also collected for patients with similar disease activity who are receiving conventional DMARDS. The BSRBR-RA is on the NIHR CLRN portfolio database which means that hospitals can claim financial support for registering patients with BSRBR-RA. If you require assistance with the BSRBR-RA study click on this link for further information.

The BSRBR-RA is supported by a team based at the Arthritis Research UK Epidemiology Unit at the University of Manchester, and directed by the principal investigator Prof. Kimme Hyrich. They provide an extensive range of services, including local investigator liaison, data management, pharmacovigilance, analysis and reports. Please refer to the contacts page for more information.

 

 

Below you will find some important information about BSRBR-RA. 

Introduction and background to the BSRBR-RA
Rheumatoid arthritis recruitment news